tiprankstipranks
CNBX Pharmaceuticals (CNBX)
OTHER OTC:CNBX

CNBX Pharmaceuticals (CNBX) Stock Price & Analysis

118 Followers

CNBX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range<$0.01 - $0.05
Previous Close$0.01
Volume30.12K
Average Volume (3M)235.06K
Market Cap
$362.55K
Enterprise Value$1.64M
Total Cash (Recent Filing)$37.14K
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)-0.2
Beta0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding31,111,352
10 Day Avg. Volume91,297
30 Day Avg. Volume235,065
Standard Deviation0.52
R-Squared0.00764
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.16
Price to Sales (P/S)9.17
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.04
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda-2.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

0.00%0.00%<0.01%100.00%
0.00%
Insiders
0.00%
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

CNBX FAQ

What was CNBX Pharmaceuticals’s price range in the past 12 months?
CNBX Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
    What is CNBX Pharmaceuticals’s market cap?
    Currently, no data Available
    When is CNBX Pharmaceuticals’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were CNBX Pharmaceuticals’s earnings last quarter?
    Currently, no data Available
    Is CNBX Pharmaceuticals overvalued?
    According to Wall Street analysts CNBX Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does CNBX Pharmaceuticals pay dividends?
      CNBX Pharmaceuticals does not currently pay dividends.
      What is CNBX Pharmaceuticals’s EPS estimate?
      CNBX Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does CNBX Pharmaceuticals have?
      CNBX Pharmaceuticals has 31,111,353 shares outstanding.
        What happened to CNBX Pharmaceuticals’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of CNBX Pharmaceuticals?
        Currently, no hedge funds are holding shares in CNBX
        ---

        CNBX Pharmaceuticals Stock Smart Score

        N/A
        Not Ranked
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Technicals

        SMA
        Negative
        20 days / 200 days
        Momentum
        -38.88%
        12-Months-Change

        Fundamentals

        Return on Equity
        Trailing 12-Months
        Asset Growth
        -64.52%
        Trailing 12-Months

        Company Description

        CNBX Pharmaceuticals

        Cannabics Pharmaceuticals, Inc. is an early stage biotechnology company, which engages in the development of personalized anti-cancer and palliative treatments. It focuses on the research and development of cannabinoid-based diagnostics, anti-cancer pharmaceuticals, and palliative therapies. The company was founded by Itamar Borochov, Eyal Ballan, and Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.
        ---
        Similar Stocks
        Company
        Price & Change
        Follow
        Inmune Bio
        Citius Pharmaceuticals
        Ocugen
        CytoDyn
        Popular Stocks
        ---
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis